News

AddToAny

Google+ Facebook Twitter Twitter

Vaccine effective in preventing typhoid fever

A single dose of the typhoid conjugate vaccine Typbar TCV provides lasting efficacy in preventing typhoid fever in children aged nine months to 12 years old, according to a new study.

A nurse takes the blood pressures of a woman as she waits with an infant at Ndirande Health Centre in Blantyre on February 21, 2018 - Image credit - Getty-922184246

Results from the phase three clinical study, conducted by researchers at the University of Maryland School of Medicine and led by in-country partners at the Malawi-Liverpool Wellcome Trust Clinical Research Programme, have been published in The Lancet.

The research team enrolled more than 28,000 healthy children in Malawi and randomly assigned about half the group to receive the TCV and the other half to receive a meningococcal capsular group A conjugate (MenA) control vaccine.

During the more than four years of follow-up, 24 children in the TCV group and 110 in the MenA group developed typhoid fever.

That resulted in an efficacy of 78.3% in the TCV group, with one case of typhoid prevented for every 163 children vaccinated.

TCV was effective in all age groups. Over the study period, which ended in 2022, vaccine efficacy only decreased by 1.3% per year.

Typhoid fever causes more than nine million illnesses and at least 110,000 deaths worldwide every year, mostly in sub-Saharan Africa and southeast Asia.

It is a contagious bacterial infection that occurs from consuming contaminated food or drink. Symptoms include nausea, fever, and abdominal pain that, if left untreated, can be deadly.

“These findings have significant implications for identification of the contribution of TCVs in the control and potential elimination of typhoid fever in endemic settings,” wrote the authors of a commentary published with the study.

bit.ly/49gkVWN

Image credit | Getty

Related Articles

eProtein Discovery side-CREDIT_Supplied

Tech round up: June 2024

Best new tech this month

Natural-killer cells attacking a cancer cel - CREDIT - Science-Photolibrary-f0339843

Predictive model for tumour-killing cells

Scientists have developed a powerful predictive model for identifying the most potent cancer-killing immune cells for use in cancer immunotherapies.

Vaccine bottle - CREDIT - iStock-Shutterstock-Various

Personalised vaccines: A pioneering new immunotherapy

A look at the international trial of the world’s first personalised mRNA cancer immunotherapy for melanoma and its potential translation to other cancers and diseases.

Oxford Autoimmune Neurology Diagnostic Laboratory -CREDIT-Supplied

My lab: antibodymediated autoimmune neurology

A guided tour of the Oxford Autoimmune Neurology Diagnostic Laboratory.

Top